Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. A computational platform to improve the prioritization of drugs and target genes for therapeutic intervention

    SBC: Genetic Networks, LLC            Topic: 100

    Project Summary This project proposes further development of a computational discovery platform shown to quantifiably identify and prioritize both targets and compounds for therapeutic interventionwhich will accelerate the development of newermore effective drugs with fewer side effectsThis platform is based on a novel fusion of two state of the art computational approachesphenolog mapping and fun ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A

    SBC: KJ Biosciences LLC            Topic: NIAID

    Salmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. An integrated electrical impedance myography platform for neuromuscular disease classification and diagnosis

    SBC: Myolex Inc            Topic: 103

    Project SummaryImproved methods for the bedside diagnosis and evaluation of neuromuscular disorders are neededOne technology that is finding increasing use for this purpose is electrical impedance myographyEIMIn EIMa very weakhigh frequency electrical current is passed through a muscle of interest and the resulting surface voltages are measuredDisease associated alterations in the composition and ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty

    SBC: Longeveron LLC            Topic: NIA

    Aging Frailty is a biologically driven geriatric syndrome of multisystem physiological decline that is distinct from normal aging and disproportionately increases vulnerability to adverse clinical outcomesFrailty has an overall prevalence ofof thoseyears and olderand there is growing awareness in the geriatric community to diagnose and treat this conditionas it is not an inevitable consequence of ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome

    SBC: Longeveron LLC            Topic: NIA

    The metabolic syndromeMetSis a cluster of factors that increases the risks for cardiovascular diseasetypediabetes mellitusand mortalityand currently affects andgtof US adultsMetS is associated with endothelial dysfunctiondecreased circulating endothelial progenitor cellsEPCsand a pro inflammatory stateWe have made the exciting discovery that therapy with allogeneic mesenchymal stem cellsMSCsrestor ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Automated Intestinal Electrical Stimulation for Diabetes

    SBC: Transtimulation Research Inc.            Topic: 200

    Diabetes affects more thanof Americans and costs over $billion inin USAMedical therapies have limitations in treating diabetic patients with obesity due their common side effects of weight gainBariatric surgery has been proposed for treating diabetic patients with promising outcomesIn this projectwe propose a novel method of intestinal electrical stimulationIESfor treating diabetesPhysiologicallyt ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Neonatal Abstinence Syndrome Therapy

    SBC: Mu Therapeutics Inc.            Topic: NIDA

    Project Summary Neonatal Abstinence SyndromeNAShas skyrocketed in recent years as a result of the opioid epidemic plaguing this countrySincethe number of babies affected by NAS has increased nearlyfoldEveryminutes a baby is born suffering from opioid withdrawaloften prematurely with developmental problems and potential long term adverse effects including cognitive impairmentApproximatelyof pregnan ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an integrated 4-organ animal model

    SBC: Hesperos, Inc.            Topic: NIEHS

    Project Summary AbstractWe propose to construct multi organ microphysiological systemsBody on a Chipor BoaCsfrom human and rat cells to use as a basis to understand species differences in response to exposure to drugs or chemicals in this new platformThe results will then be compared to clinical datawhere availableand to archived in vivo animal dataThis work will directly test whether such in vitr ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIA

    Abstract PTI is developing PTIDXa novelquantitative blood based diagnostic candidate for Alzheimerandapos s diseaseADA non invasive and inexpensive AD diagnostic is sorely neededparticularly one with the ability to detect early pathological changes that precede cognitive symptomsPTIDX measures the ratio of two protein fragments in plasma and is a companion diagnostic biomarker for our therapeutic ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL an Innate Immune Stimulant

    SBC: PULMOTECT, INC            Topic: NHLBI

    Pulmotect Inc was founded in to translate discoveries that induce innate immune resistance in the lung into therapeutics that will provide protection from inhaled pathogens Our technology platform is a direct result of basic research by our founders on the mechanisms of microbial resistance in the lung epithelium We have developed an inhaled therapeutic PUL that provides immediate p ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government